AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
79% vaccine efficacy at preventing symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalisation Comparable efficacy result across ethnicity and age, with 80% efficacy in participants aged 65 years and over Favourable reactogenicity and overall safety profileThe AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. This interim safety and efficacy analysis was based on 32,449 participants accruing